---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-054797"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:23:56.111759+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics regains Nasdaq compliance on minimum bid price requirement

## Summary
- Received Nasdaq letter on Feb 17, 2026 confirming compliance with Listing Rule 5550(a)(2).
- Had been non-compliant since Feb 21, 2025; deadline extended to Feb 17, 2026.
- Met requirement by maintaining $1.00+ closing bid for 10 consecutive trading days through Feb 13, 2026.
- Common stock will continue listed on The Nasdaq Capital Market without interruption.

## SEC filing metadata
- accession: 0001193125-26-054797
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312526054797/0001193125-26-054797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526054797/atos-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-054797
- JSON: https://secwatch.observer/filing/0001193125-26-054797.json
- Plain text: https://secwatch.observer/filing/0001193125-26-054797.txt

## Source-grounded claims
- claim_id: 4d1b195e36688b82b6b5589ee40afafa2c7d0281
  claim: ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: February 17, 2026, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on February 21, 2025, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000119312526054797/0001193125-26-054797-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.